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SUMMARY 
Background: The occurrence of endocrine diseases in people who are infected with HIV is traditionally thought to 
occur in the setting of AIDS with opportunistic infections and malignancies. However, recent studies find the corre-
lation between hypocortisolism and stage of HIV (CD4 count and WHO clinical stage) inconsistent. 
Methods: This descriptive cross-sectional study included three hundred and fifty (350) consecutive patients with 
HIV infection. They were interviewed, and subsequently underwent laboratory evaluation for the detection of hypo-
cortisolism. Blood samples for serum cortisol estimation were taken at baseline and at 30 minutes following the ad-
ministration of 1μg of tetracosactrin (Synacthen). In addition, the patients had blood samples taken at 0 minutes 
(baseline) for CD4+ lymphocyte cell counts. 
Results: At baseline, 108 (30.9%) participants had serum cortisol levels below 100 μg/L with a median value of 
55.48 μg/L (11.36-99.96 μg/L), but only 57 (16.3%) study participants had stimulated serum cortisol levels below 
180 μg/L with median of 118 μg/L (19.43-179.62). There was no significant difference in the occurrence of clinical 
features between participants with low and normal serum cortisol, nor WHO clinical stage, CD4 count and ART 
regimen. The occurrence of hypocortisolism was higher among participants who had been on ART for a longer peri-
od of time. 
Conclusion: There is a high prevalence of hypocortisolism among HIV patients by biochemical testing, especially 
those who have been on ARVs for a longer duration. Hypocortisolism cannot be predicted based on the participants’ 
WHO clinical stage of disease, CD4 cell count, or the treatment regimen.  
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INTRODUCTION 
The human immunodeficiency virus type-1 (HIV-1) 
infection and its sequelae, the acquired immune defi-
ciency syndrome (AIDS) are major causes of morbidity 
and mortality worldwide, accounting for over 35 million 
deaths.1 Endocrine diseases, including dyslipidemia, 
disorders of bone homeostasis, and dysfunction of the 
adrenal, gonadal, and thyroid axes were reported in 
HIV-infected persons early in the HIV epidemic prior to 
the availability of HAART.2 The occurrence of endo-
crine diseases in people who are infected with HIV is 
traditionally thought to occur in the setting of AIDS 
with opportunistic infections and malignancies.3, 4 
 
However, even in the setting of sustained treatment of 
HIV infection with highly active anti-retroviral therapy 
(HAART) and a fully suppressed HIV RNA, there is an 
associated heightened systemic inflammation and im-
mune dysfunction, albeit at lower levels than without 
antiretroviral treatment.5 This state of persistently 
heightened inflammation may account for certain endo-
crine and cardiovascular complications of HIV.6 
 
Adrenal diseases are thought to be the commonest en-
docrine abnormality in HIV, with autopsy studies show-
ing involvement of the adrenal glands in 40-90% of 
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A study done in Lagos, Nigeria among 44 newly diag-
nosed, treatment naïve persons with HIV infection re-
ported a 34.8% prevalence of hypoadrenalism.8Meyaet 
al found the prevalence of functional adrenal insuffi-
ciency in critically ill HIV patients in Makerere to be 
19%.9 A similar study done in South Africa involving 66 
consecutive subjects diagnosed with HIV admitted to 
the medical wards of the Nelson Mandela Academic 
Hospital in a 3-month period revealed a prevalence of 
27%.10 
 
The occurrence of adrenal insufficiency among patients 
infected with HIV has been noted to occur more com-
monly among patients with advanced HIV infection 
with low CD4 counts and the presence of many oppor-
tunistic diseases.3, 4 However, some studies have noted 
that the relationship between CD4 cell count and adren-
al insufficiency has not been consistent and predictable, 
with the study in Lagos showing a poor correlation.8 
 
The aim of this study was to evaluate the occurrence of 
hypocortisolism among HIV patients, and determine the 
relationship between hypocortisolism, the clinical stage 
of HIV, the CD4 count and the ART regimen of patients 
who were attending the HIV clinic at the Aminu Kano 
Teaching Hospital (AKTH), Kano. 
 
METHODS 
This study was descriptive cross-sectional study, con-
ducted at AKTH, Kano. The study subjects included 
three hundred and fifty (350) consecutive patients with 
HIV infection presenting at the ART clinic of AKTH 
Kano. Recruited patients were adults (≥18 years), who 
were confirmed to have HIV infection according to the 
serial testing algorithm in accordance with the national 
guidelines. Participants were recruited from September 
2015 to January 2016. All the recruited patients were 
interviewed for features suggestive of hypoadrenalism. 
They subsequently underwent laboratory evaluation for 
the detection of hypocortisolism. Patients presenting in 
Addisonian crisis, those who were on steroids, and other 
drugs that could interfere with adrenal function (e.g. 
ketoconazole, phenytoin, rifampicin) were excluded 
from the study. 
 
Patients’ clinical data were collected using an inter-
viewer administered questionnaire. Blood samples for 
serum cortisol estimation were taken at baseline and at 
30 minutes following the administration of 1μg of tetra-
cosactrin (Synacthen). In addition, the patients had 
blood samples taken at 0 minutes (baseline) for CD4+ 
lymphocyte cell counts.The short Synacthen test was 
conducted in the morning between 8:00 AM and 
9:00AM.  
All the recruited participants had serum measurement 
both at baseline and 30 minutes after Synacthen admin-
istration. After explaining the procedure to the patient, 
1µg of Synacthen was prepared by adding 250µg of 
tetracosactrin (Synacthen) (1mL) into 499 mL of normal 
saline and mixing the solution thoroughly. Each 2 mL of 
the diluted solution contained 1 µg tetracosactrin (Syn-
acthen). The solution thus prepared was sealed after 
each usage and stored in a refrigerator at 4-80 C.  
 
After securing a venous access, the site was observed 
for the presence of hematoma or bleeding. One mL of 
normal saline was then injected to ensure patency of the 
vein, and 3 mL of blood was taken at 0 minutes, follow-
ing which, 1 µg of Synacthen was injected intravenous-
ly. Another 3 mL of blood was drawn after 30 minutes. 
All the blood samples were kept on ice slabs and trans-
ported to the laboratory using ice packs for separation 
and storage of the serum at -200C until assayed. Estima-
tion of serum cortisol was done after pooling of sam-
ples. The Calbiotech® Cortisol ELISA kit (Calbiotech 
Inc., Spring Valley, CA, USA) was used for the serum 
cortisol assay. Adrenal insufficiency was defined as less 
than 145 µg/L (400 nmol/L) using early morning basal 
serum cortisol and a 30-minute post-ACTH (stimulated) 
serum cortisol level of less than 180 µg/L (500 nmol/L). 
 
All data were analyzed using Statistical Package for 
Social Sciences (SPSS), version 20.0, Chicago, IL USA. 
Participants’ serum cortisol was presented as median 
with range while other quantitative variables like age 
and BMI were presented as means and standard devia-
tion. The qualitative variables were presented as propor-
tions and percentages. Statistical test of significance at 
5% alpha level was done using the appropriate test sta-
tistic and were considered significant for p values < 
0.05. The student t-test was used to compare the means 
of quantitative variables while the Mann-Whitney U test 
was used to compare the medians of the stimulated se-
rum cortisol among participants with normal serum cor-
tisol and those with hypoadrenalism. The χ2 test was 
used as the test estimate for qualitative data. Logistic 
regression analysis was carried out to determine the 
predictors of hypocortisolism among the participants. 
 
The Health Research and Ethical Committee of AKTH 
approved the study. Written informed Consent was ob-
tained from each participant after demonstrating a satis-
factory level of understanding regarding the nature and 
extent of their involvement and had willingly agreed to 
participate. Information and data derived were kept con-
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RESULTS 
The mean age of the study participants was 39.75 ± 9.22 
years, with a mean of 40.0 ± 9.21years among those 
participants with a normal adrenal function and 38.49 ± 
9.21 years among those with hypoadrenalism respec-
tively (mean difference 1.51, 95% CI= -1.12 to 4.13, p= 
0.53). Male gender constituted 49.1% (172) of the study 
participants while 50.9% (178) were female. 
 
Serum cortisol 
Analysis of the baseline serum cortisol showed that 108 
(30.9%) of the study participants had serum cortisol 
levels below 100 μg/L with a median value of 55.48 
μg/L (11.36-99.96 μg/L), in comparison to participants 
with a normal baseline serum cortisol, among whom the 
median serum cortisol was 150.26 μg/L (101-525 μg/L). 
(Median difference = 94.78, p< 0.001, Mann-Whitney 
U test) 
 
Following the administration of 1 μg ACTH, 57 
(16.3%) participants had measured serum cortisol val-
ues of less than 150 μg/L with a median value of 98 
μg/L (19.43-149.62), while 293 (83.7%) had normal 
serum cortisol with a median serum cortisol of 221.69 
μg/L (151.91-865.23). (Median difference = 123.69, 
p<0.001, Mann-Whitney U test) 
 
Clinical features 
The commonest observed symptom among participants 
with hypocortisolism was anorexia, which was observed 
among 13 (22.8%) participants with low stimulated se-
rum cortisol, followed closely by weight loss, fever, 
lethargy and skin darkening. Abdominal pain occurred 
in only one participant with low stimulated serum corti-
sol (1.75%).  
 
The most commonly documented examination finding 
among participants with low stimulated serum cortisol 
was pallor (22.8%). None of the participants with hypo-
cortisolism had skin hyperpigmentation. Among the 
participants with normal stimulated serum cortisol lev-
els however, 16.0% (47) had pallor, 2.0% (6) oral thrush 
while 1.4% (4) participants were noted to have hyper-
pigmentation of the skin. 
 
There was no significant difference in the occurrence of 
various clinical features between participants with nor-
mal serum cortisol and those with hypocortisolism, ex-
cept headache (p= 0.02, χ2 test) which was commoner 
among those participants with hypoadrenalism (See 
Table 1). 
 
WHO clinical stage of disease 
Majority of the participants were in WHO clinical stage 
1 of HIV infection, among whom 80.6% (170) had a 
normal serum cortisol while 19.4% (41) had hypocorti-
solism.The proportion of hypocortisolism relative to the 
total participants in each group shows that the greatest 
proportion of participants with hypocortisolism oc-
curred within WHO clinical stage 1(19.4%) followed by 
those with stage 3 disease. The lowest proportion of 
participants with hypocortisolism occurred within par-
ticipants with stage 4 disease (p=0.27, χ2 test), as shown 
in Table 2. 
 




(n = 57) 
Normal  
(n = 273) 
p value* 
SYMPTOMS  
Anorexia 13 (22.8%) 57 (19.5%) 0.56 
Weight loss 10 (17.5%) 54 (18.4%) 0.87 
Fever 9 (15.8%) 44 (15%) 0.88 
Lethargy  9 (15.8%) 51 (14.6%) 0.77 
Skin Hyperpigmentation 7 (12.3%) 30 (10.2%) 0.65 
Body itching 6 (10.5%) 36 (12.3%) 0.71 
Headache 6 (10.5%) 10 (3.4%) 0.02 
Skin rashes 5 (8.7%) 29 (9.9%) 0.79 
Abdominal pains 1 (1.75%) 9 (3%) 0.59 
Diarhhoea 0 8 (2.7%) 0.21 
Pallor 13 (22.8%) 47 (16%) 0.22 
Oral thrush 2 (3.5%) 6 (2%) 0.49 
Dyspigmentation 0 4 (1.4%) 0.38 
Hepatomegaly 0 2 (0.7%) 0.53 
*= χ2 test 
 
Duration from diagnosis of HIV 
The highest proportion of the participants with low 
stimulated serum cortisol were found among partici-
pants who had been on treatment for a duration of be-
tween 6-10 years (20.4% [21 out of 103]) followed by 
those who had been on treatment for greater than 10 
years (18.2% [4 out of 22]). Among the newly diag-
nosed (i.e. yet to commence HAART) participants, 
13.6% (8 out of 59) had hypoadrenalism, while 14.5% 
(24 out of 166) of participants who had been on treat-
ment for 1-5 years had hypoadrenalism (p= 0.006, χ2 
test).The participants that had adrenocortical insuffi-
ciency were noted to have had a longer duration from 
diagnosis compared to those that had a normal adrenal 
function (4.96 years versus 4.38 years, mean difference 
= -0.583, p= 0.28). 
 
Serum CD4 count 
The median current CD4 T lymphocyte count among 
participants with a low stimulated serum cortisol level 
was 466 cells/µL (46-1125 cells/µL), compared to CD4 
cell counts of 372 cells/µL (14-1125 cells/µL), (Median 
difference = 94, p= 0.10, Mann-Whitney U test) in par-
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The participants with CD4 counts greater than 500 
cells/µL had the highest prevalence of hypocortisolism, 
with 19.1% (22 out of 115) of the participants with CD4 
counts greater than 500 cells/µL noted to have low 
stimulated cortisol. There was a negative correlation 
between the participants’ current CD4 counts and meas-
ured serum cortisol, with correlations of -0.073 (p= 
0.23) and -0.152 (p= 0.012) with the baseline and the 
stimulated serum cortisol concentrations respectively.  
 
Table 2 Participants’ clinical parameters and CD4 cell 
counts 







Stage I 170 41 19.4% 
Stage II 69 9 11.5% 
Stage III 43 6 12.2% 
Stage IV 11 1 8.3% 
BMI (Kg/m2) Underweight 43 7 14.0% 
Normal weight 145 25 14.7% 
Overweight 80 17 17.5% 
Obese 22 7 24.1% 
CD4 Count  
(cells/ mm3) 
<200 55 7 11.3% 
200-500 145 28 16.2% 
>500 93 22 19.1% 
 
ART regimen 
The greatest proportion of the participants with low 
serum levels of stimulated cortisol were taking the 
AZT/3TC/NVP regimen (21.6% [24 out of 111]) fol-
lowed by the TDF/3TC or FTC/EFV regimen (15.9% 
[21 out of 132]). Among participants who were yet to 
commence medications, 12.9% (8 out of 62) had hypo-
cortisolism. A logistic regression analysis was conduct-
ed to predict the occurrence of hypocortisolism using 
duration of treatment, current CD4 count, WHO clinical 
stage, and treatment regimen as predictors. A test of the 
full model against a constant only model was not statis-
tically significant, indicating that the predictors as a set 
did not reliably distinguish between the presence of 
hypocortisolism and normal serum levels (χ2 = 17.99, 
p= 0.59, df = 20). Nagelkerke’s R2 of 0.12 indicated a 
weak relationship between prediction and grouping. 
Prediction success overall was 82.2% (99.1% for nor-




The highest proportion of study participants with hy-
poadrenalism as measured with stimulated serum corti-
sol measurement was observed among participants who 
had WHO clinical stage 1 disease, although it is worthy 
of note that this group also had the highest number of 
participants in the study. It was also noted in this study 
that the CD4 cell count was higher among participants 
who had hypocortisolism compared to those with nor-
mal adrenal function.  
Similarly, majority of participants with hypocortisolism 
in this study as measured by stimulated serum cortisol 
had no distinguishing symptoms traditionally thought to 
be suggestive of adrenocortical insufficiency.  
 
On the other hand, most of the patients with normal 
serum cortisol had features which may be seen in pa-
tients with adrenocortical insufficiency. This is con-
sistent with findings by other authors who have noted a 
poor correlation between clinical features suggestive of 
hypoadrenalism in HIV patients with adrenal insuffi-
ciency.8,9,11 In the study by Meyaet al, symptoms of 
fatigue, anorexia, weight loss and vomiting all occurred 
with similar frequency among those who had adrenal 
insufficiency and those with normal cortisol function.9 
 
Various studies done elsewhere have demonstrated a 
higher prevalence of hypoadrenalism in HIV patients 
with advanced disease (Stage 3 and 4), which may re-
flect opportunistic infections and malignancies that are 
more likely to occur in that group of patients due to de-
clining immunological function.11-13 Meyaet al found 
that HIV stage 4 disease was associated with higher 
prevalence of adrenal insufficiency.10 Even though the 
difference in median CD4 count between participants 
with hypoadrenalism and those with normal serum cor-
tisol was not statistically significant, there was a signifi-
cant inverse correlation between the CD4 count and the 
stimulated serum cortisol levels. 
 
In this study, the highest proportion of patients with 
hypoadrenalism was on the AZT/3TC/NVP regimen. 
Due to the study design, a cause and effect relationship 
cannot be established for this drug regimen in relation to 
adrenocortical insufficiency. However, it is worthy of 
note that patients on this combination were more likely 
to have been on ARTs for a longer period than those on 
other combinations, and any effect of the drug may ac-
tually have been due to a longer duration of HIV infec-
tion and not due to the drug itself, as demonstrated in 
the inverse correlation between stimulated serum corti-
sol levels and duration of disease. It could be that the 
pattern of the occurrence of adrenal diseases in HIV 
patients is changing, and the aetiological factors respon-
sible for hypoadrenalism may be shifting from oppor-
tunistic diseases to inflammatory mediators and meta-
bolic disturbances that seem to persist even in the face 
of suppressed viral load,4 especially in patients who 
have been on ARVs for a prolonged period of time (as 
was observed in this study). This changing picture may 
have ramifications for the current policy of early com-
mencement of ARVs in all HIV infected patients irre-
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While numerous studies have shown morbidity and 
mortality benefits with early commencement of ARVs, 
15, 16 there are lingering concerns about the long-term 
effects of the prolonged use of ARVs in this population. 
There is need therefore, for further study to clearly de-
fine the long-term effects of ARVs on the metabolic and 
endocrine outcomes of HIV patients, and establish 
whether there is indeed a changing picture in the occur-
rence of adrenal diseases in this group of patients. 
 
This study was limited by our inability to evenly dis-
tribute the participants into the various WHO clinical 
stages by virtue of the fact that the sampling was a con-
venient one. Additionally, our inability to measure other 
adrenal hormones limited our inferences to adrenocorti-
cal function, and not hypoadrenalism. 
 
CONCLUSION 
There is a high prevalence of hypocortisolism among 
HIV patients by biochemical testing, especially those 
who have been on ARVs for a longer duration. The oc-
currence of hypocortisolism, however, cannot be pre-
dicted based on the participants’ WHO clinical stage of 
disease, CD4 cell count, or the treatment regimen.  
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